CBD

Cannabidiol, almost always abbreviated CBD, is a phytocannabinoid first described in the 1940s and one of the most abundant compounds in cannabis, where it can make up a large share of the plant's extract ^[3]. Chemically it is closely related to tetrahydrocannabinol (THC) and shares much of the same biosynthetic pathway, but it is non-intoxicating and does not produce the characteristic cannabis high. Its structure and stereochemistry were worked out in the 1960s, and it has since become one of the most studied cannabinoids ^[3].

The clearest evidence for CBD lies in epilepsy. A purified, plant-derived cannabidiol oral solution (sold as Epidiolex, or Epidyolex in Europe) is approved for seizures associated with rare, severe syndromes including Dravet syndrome and Lennox-Gastaut syndrome, and later for tuberous sclerosis complex. In a landmark randomized, placebo-controlled trial, adding cannabidiol to standard therapy significantly reduced convulsive-seizure frequency in children with Dravet syndrome ^[1]. Comparative analyses place it alongside other add-on options such as stiripentol and fenfluramine, with differences in efficacy and tolerability ^[4].

Beyond epilepsy, CBD has been investigated for anxiety, chronic pain, inflammation, psychosis, and substance use, and laboratory work suggests effects on mood-related circuits; in animal models it produced rapid antidepressant-like effects that depended on serotonin 5-HT1A receptors ^[2]. Reviews note that CBD interacts with a broad set of targets, including the 5-HT1A receptor, rather than binding strongly to the classical cannabinoid receptors, but for most of these non-epilepsy uses the clinical evidence is still considered preliminary ^[3].

Regulation of CBD is complex and varies widely. In the United States the prescription epilepsy product is an approved drug, while hemp-derived CBD containing little THC occupies a legal gray area and is not formally permitted as a food or dietary supplement even though it is sold widely; other countries take differing approaches. It is available in many forms, from the prescription oral solution to oils, tinctures, capsules, edibles, and vaporizer products, and as a component of the mouth spray nabiximols that combines CBD with THC. Reported side effects include sleepiness, diarrhea, reduced appetite, and fatigue, and it can interact with other medicines and affect liver enzymes ^[1][3].

Highly purified pharmaceutical CBD (Epidiolex) has been evaluated in large controlled epilepsy trials, so its safety profile is unusually well characterized for a cannabis-derived compound. The most common adverse effects are somnolence and sedation, diarrhea, reduced appetite, fatigue, and (in children) fever and vomiting; these are generally dose-dependent and often improve with dose reduction. The most clinically watched signal is dose-dependent elevation of liver transaminases (ALT/AST); in the tuberous sclerosis trial roughly one in five patients on CBD had raised liver enzymes versus none on placebo, and the risk is amplified when CBD is combined with valproate. Baseline and periodic liver-function monitoring is therefore standard, and CBD is used cautiously in people with hepatic impairment.

The biggest practical hazard is drug interactions. Because CBD inhibits CYP3A4 and CYP2C19 (and is a substrate of those pathways), it can raise blood levels of many co-administered medications. The best-documented example is clobazam: CBD markedly increases the active metabolite N-desmethylclobazam, boosting both benefit and sedation, so clobazam doses often need lowering. CBD can also increase exposure to other antiepileptics and has been reported to potentiate warfarin, raising the INR and bleeding risk, which means anyone on warfarin or other narrow-therapeutic-index drugs should have levels monitored when CBD is started or stopped. Caution is warranted with other CNS depressants and alcohol given additive sedation.

CBD is not recommended in pregnancy or breastfeeding; safety data are lacking and animal studies raise reproductive concerns. A separate, real-world caveat is product quality: most over-the-counter CBD is unregulated and frequently mislabeled, with actual CBD content differing from the label and occasional contamination with THC, solvents, or heavy metals, so consumer products do not carry the safety assurances of the approved pharmaceutical. CBD itself has low abuse potential and no meaningful intoxication, but it should not be treated as risk-free, particularly for people taking other medications.

Cannabidiol was first isolated in 1940 by the American chemist Roger Adams and colleagues at the University of Illinois, although its correct chemical structure was not fully determined until 1963, when Raphael Mechoulam and Yechiel Gaoni at Israel's Weizmann Institute elucidated it, shortly before they characterized THC. For decades CBD remained a scientific curiosity, overshadowed by the intoxicating THC, but interest surged in the 2010s as case reports suggested benefit in severe childhood epilepsy.

A landmark double-blind, placebo-controlled trial led by Orrin Devinsky, published in 2017, showed that purified cannabidiol significantly reduced convulsive seizures in children with Dravet syndrome. On the strength of such trials, the United States Food and Drug Administration approved a purified pharmaceutical formulation, Epidiolex, in June 2018 for certain rare epilepsies; it was the first cannabis-derived medicine ever cleared in the United States. Outside that narrow approval, CBD is now sold worldwide as a largely unregulated supplement.

CBD has become one of the most talked-about natural compounds of the modern era, and part of its appeal is scientific rather than merely commercial. Its ability to calm the devastating seizures of Dravet and Lennox-Gastaut syndromes, where many conventional drugs fail, is well documented and earned it a place in mainstream medicine.

Equally intriguing is its pharmacological complexity; rather than acting through a single receptor, CBD touches a remarkably wide array of targets, from serotonin 5-HT1A receptors linked to its calming effects to ion channels implicated in its anti-seizure activity, which helps explain the breadth of effects people report. It achieves all of this without producing a high, distinguishing it sharply from THC. That said, an honest reading of the evidence is important; outside of the approved epilepsy uses, high-quality clinical data for anxiety, pain, and sleep remain limited, and product quality in the unregulated market varies widely.